Abstract
Objectives: This study aimed to assess whether topical anorectal application of an ointment containing nifedipine (0.3% w/w) and lidocaine (lignocaine) [1.5% w/w] to patients undergoing Milligan-Morgan haemorrhoidectomy achieves pharmacologically relevant serum concentrations of the active ingredients and has any haemodynamic effects or adverse effects.
Methods: A single dose of 3 g of study ointment was circumferentially applied inside the anus to 24 patients (17 males and 7 females) aged 23–71 years (mean ± SD: 42.9 ± 4.9 years) during postoperative dressing after Milligan-Morgan haemorrhoidectomy from March 2007 to January 2008. Blood samples for the determination of nifedipine and lidocaine serum concentrations were drawn before surgery and at 20, 40, 60, 90, 120, 240, 360, 480 and 720 minutes after application. Serum concentrations of nifedipine and lidocaine were determined by a high-performance liquid chromatography method in order to calculate pharmacokinetic parameters. Patients’ BP, heart rate and ECG readings were monitored during the study.
Results: Chromatographic signals of nifedipine were sporadically observed in only five patients (20.8%), consistent with therapeutically negligible concentrations and insufficient to permit calculation of any pharmacokinetic parameters. The serum concentrations of nifedipine in these five patients ranged from 5.9 to 18.8 ng/mL. Lidocaine concentrations were detectable in all patients. The means ± SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (Cmax) 245.1±370.8 ng/mL, 73.6 ng/mL; time to reach Cmax (tmax) 69.2±78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC6) 756.5±1254.1 ng·h/mL, 238.2 ng·h/mL. Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL). These outlier concentrations were four to five times lower than the threshold of CNS lidocaine toxicity (5000–6000 ng/mL). No serious local or systemic adverse events were observed throughout the study, and no subjects developed arrhythmias or significant ECG changes. Neither BP nor mean heart rate varied significantly after application of a single dose.
Conclusions: This study demonstrates that single-dose topical application of an ointment containing nifedipine (0.3% w/w) and lidocaine (1.5% w/w) to patients undergoing Milligan-Morgan haemorrhoidectomy is safe to use. Following application onto damaged anorectal mucosa, nifedipine and lidocaine are absorbed into the bloodstream in small quantities that do not have any major implications for the safety of the product. Further studies are required to evaluate nifedipine and lidocaine concentrations in serum using a multiple-dose regimen.
Similar content being viewed by others
References
Nisar PJ, Scholefield JH. Managing haemorrhoids. BMJ 2003; 327: 847–51
Goldstein ET, Williamson PR, Larach SW. Subcutaneous morphine pump for postoperative hemorrhoidectomy pain management. Dis Colon Rectum 1993; 36: 439–46
Carapeti E, Kamm M, McDonald P, et al. Double-blind randomised controlled trial of effect of metronidazole on pain after day-case haemorrhoidectomy. Lancet 1998; 351: 169–72
Wasvary HJ, Hain J, Mosed-Vogel M, et al. A randomized, prospective, double-blind, placebo-controlled trial of effect of nitroglycerin ointment on pain after hemorrhoidectomy. Dis Colon Rectum 2001; 44: 1069–73
Deutsch AA, Moshkovitz M, Nudelman I, et al. Anal pressure measurements in the study of hemorrhoid etiology and their relation to treatment. Dis Colon Rectum 1987; 30: 855–7
Roe AM, Bartolo DC, Vellacott KD, et al. Submucosal versus ligation excision haemorrhoidectomy: a comparison of anal sensation, anal sphincter manometry and postoperative pain and function. Br J Surg 1987; 74: 948–51
Kanellos I, Zacharakis E, Christoforidis E, et al. Usefulness of lateral internal sphincterotomy in reducing postoperative pain after open hemorrhoidectomy. World J Surg 2005; 29: 464–8
Goligher JC, Graham NG, De Dombal FT, et al. The value of stretching of anal sphincters in the relief of pain after haemorrhoidectomy [abstract]. Br J Surg 1969; 56: 390
Ho YH, Seow-Choen F, Low JY, et al. Randomised controlled trial of trimebutine (anal sphincter relaxant) for pain after haemorrhoidectomy. Br J Surg 1997; 84: 377–9
Davies J, Duffy D, Boyt N, et al. Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study. Dis Colon Rectum 2003; 46: 1097–102
Nicholson TJ, Armstrong D. Topical metronidazole (10 percent) decreases posthemorrhoidectomy pain and improves healing. Dis Colon Rectum 2004; 47: 711–6
Vinson-Bonnet B, Coltat JC, Fingerhut A, et al. Local infiltration with ropivacaine improves immediate postoperative pain control after hemorrhoidal surgery. Dis Colon Rectum 2002; 45: 104–8
Coskun A, Duzgun SA, Uzunkoy A, et al. Nitroderm TTS® band application for pain after hemorrhoidectomy. Dis Colon Rectum 2001; 44: 680–5
Colak T, Akca T, Dirlik M, et al. Micronized flavonoids in pain control after hemorrhoidectomy: a prospective randomized controlled study. Surg Today 2003; 33: 828–32
Elton C, Sen P, Montgomery AC. Initial study to assess the effects of topical glyceryl trinitrate for pain after haemorrhoidectomy. Int J Surg Investig 2001; 2: 353–7
Chrysos E, Xynos E, Tzovaras G, et al. Effect of nifedipine on rectoanal motility. Dis Colon Rectum 1996; 39: 212–6
Antropoli C, Perrotti P, Rubino M, et al. Nifedipine for local use in conservative treatment of anal fissures: preliminary results of a multicenter study. Dis Colon Rectum 1999; 42: 1011–5
Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. Dis Colon Rectum 2003; 46: 805–8
Perrotti P, Antropoli C, Noschese G, et al. Topical nifedipine for conservative treatment of acute haemorrhoidal thrombosis. Colorectal Dis 2000; 2: 18–21
Cook TA, Brading AF, Mortensen NJ. Effects of nifedipine on anorectal smooth muscle in vitro. Dis Colon Rectum 1999; 42: 782–7
Cook TA, Brading AF, Mortensen NJ. Differences in contractile properties of anorectal smooth muscle and the effects of calcium channel blockade. Br J Surg 1999; 86: 70–5
Perrotti P, Bove A, Antropoli C, et al. Topical nifedipine with lidocaine ointment versus active control for treatment of chronic anal fissure: results of a prospective, randomized, double-blind study. Dis Colon Rectum 2002; 45: 1468–75
Perrotti P, Antropoli C, Molino D, et al. Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine. Dis Colon Rectum 2001; 44: 405–9
Perrotti P, Grumetto L, Barbato F, et al. Serum levels and possible haemodynamic effects following anorectal application of an ointment containing nifedipine and lignocaine: a study in healthy volunteers. Clin Drug Invest 2006; 26: 459–67
Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5: 18–24
Traube M, Hongo M, McAllister Jr RG, et al. Correlation of plasma levels of nifedipine and cardiovascular effects after sublingual dosing in normal subjects. J Clin Pharmacol 1985; 25: 125–9
Kurosawa S, Kurosawa N, Owada E, et al. Rectal administration of nifedipine: hemodynamic effects and pharmacokinetics in hypertensives. J Int Med Res 1987; 15: 121–7
Kleinbloesem CH, van Harten J, de Leede LG, et al. Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system. Clin Pharmacol Ther 1984; 36: 396–4
Covino BG. Toxicity of local anesthetic agents. Acta Anaesthesiol Belg 1988; 39(3 Suppl. 2): 159–64
Tucker GT. Clinical pharmacokinetics of local anesthetics. Clin Pharmacokinet 1979; 4: 241–78
Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986 Nov; 11(6): 425–49
Covino BG. Pharmacology of local anesthetics. Br J Anaesth 1986; 58: 701–16
Tonsuwannont W, Praisontarangkul OA, Manorot M, et al. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. J Med Assoc Thai 1996 May; 79(5): 309–19
Hardman JG, Limbird LE, Molinoff PB, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1195; 1754–65
Shiau JM, Su HP, Chen HS, et al. Use of a topical anesthetic cream (EMLA) to reduce pain after hemorrhoidectomy. Reg Anesth Pain Med 2008; 33: 30–5
Vickers ER, Marziani N, Gerzina TM, et al. Pharmacokinetics of EMLA cream 5% application to oral mucosa. Anesth Prog 1997; 44: 32–7
Leopold A, Wilson S, Weaver JS, et al. Pharmacokinetics of lidocaine delivered from a transmucosal patch in children. Anesth Prog 2002; 49: 82–7
Jensen SL. Treatment of first episodes of acute anal fissure: prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. Br Med J (Clin Res Ed) 1986; 3(292): 1167–9
McDonald P, Driscoll AM, Nicholls RJ. The anal dilator in the conservative management of acute anal fissures. Br J Surg 1983; 70: 25–6
Neiger A, Herms E. The symptomatic therapy of hemorrhoids and anal eczema: a report of experiences from proctology practice. Schweiz Rundsch Med Prax 1990; 79(31-32): 918–20
Brown AC, Sumfest JM, Rozwadowski JV. Histopathology of the internal anal sphincter in chronic anal fissure. Dis Colon Rectum 1989; 32: 680–3
Benfeldt E, Serup J, Menné T. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. Br J Dermatol 1999; 140: 739–48
Jonas M, Barrett DA, Shaw PN, et al. Systemic levels of glyceryl trinitrate following topical application to the anoderm do not correlate with the measured reduction in anal pressure. Br J Surg 2001; 88: 1613–6
Acknowledgements
Bracco SpA, Milan, Italy, provided financial support for this phase IV clinical study subject to Good Clinical Practice rules, Italian laws and local ethics committee decisions. This financial support was limited to payment of health insurance policies for patients who participated in the trial, supplying investigational products and paying institutions for the costs of material used for every patient.
Pasquale Perrotti and Carmine Antropoli are general staff and colorectal surgeons at ‘A. Cardarelli’ Hospital, Naples, Italy. They wrote this article, are independent of any financial arrangement with the pharmaceutical company whose product was tested in this study, and have no conflicts of interest that are directly relevant to the content of this study. Guglielmo Giannotti carried out surgical procedures and clinical assessments for the evaluation of safety at the Second Department of Surgery, General Hospital of Crema, Crema, Italy, and has no conflicts of interest that are directly relevant to the content of this study. Mario Regazzi and Maria Cusato are the main investigators of a certified centre of Pharmacology — Clinical Pharmacokinetic Laboratory Department of Pharmacology, Foundation IRCCS, San Matteo General Hospital, Pavia, Italy, which carried out the determinations of nifedipine and lidocaine. These investigators have no conflicts of interest that are directly relevant to the content of this study. Enzo Grossi, Patrizia Dominici and Renata Cerutti are employees of/researchers for Bracco SpA. They played a role in planning and application of the methods protocol, coordination of the institutions involved in the study, and the statistical evaluation of data. These roles were limited by Good Clinical Practice rules and Italian laws.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perrotti, P., Dominici, P., Grossi, E. et al. Pharmacokinetics of Anorectal Nifedipine and Lidocaine (Lignocaine) Ointment following Haemorrhoidectomy. Clin. Drug Investig. 29, 243–256 (2009). https://doi.org/10.2165/00044011-200929040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200929040-00003